Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quantitative flutemetamol PET/CT in cardiac amyloidosis
2020-004627-16Phase 4Completed
- Sponsor
- Helsinki University Hospital
- Start
- Oct 2020
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of flutemetamol in amyloid cardiomyopathy, sponsored by Helsinki University Hospital. Primary endpoint: Total mortality. Started Oct 2020; status: completed.
02
Drugs
flutemetamol
03
Conditions
amyloid cardiomyopathy
Beyond the preview
Go deeper on 2020-004627-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004627-16.